BioSpace counted more than 50 biopharma M&A deals in the first half, with Eli Lilly's $25 billion in deal spending leading every other acquirer by value.

The H1 tally places the year on track to exceed recent biopharma deal volumes, with the first half alone clearing the multi-year annual average. Lilly's contribution — $25 billion committed in a six-month window — accounts for a disproportionate share of disclosed transaction value across the sector.

What does Lilly's $25B tell us?

Lilly's H1 spending dwarfs the next-largest single contributor. Three observations stand out from the BioSpace analysis:

• Capital is highly concentrated. A handful of strategic acquirers — Lilly most prominently — wrote the bulk of disclosed deal value.
• Big Pharma has returned. Strategic buyers re-emerged at scale, prioritizing pipeline assets over financial engineering.
• Sellers tested the bid. Biotech boards moved quickly into market while public valuations remained volatile.

How does Lilly's $25B break down?

The $25 billion envelope spans three deal archetypes:

• Pipeline and platform deals. Earlier-stage assets in metabolic disease and adjacent indications, acquired to extend franchise leadership while valuations remain favorable.
• Adjacency plays. Targeted entries into oncology and neuroscience categories, where Lilly's existing commercial infrastructure offers integration leverage.
• Manufacturing and capacity deals. Long-cycle capacity acquisitions aimed at securing supply for high-volume commercial products.

Lilly did not disclose every individual transaction in granular form, but the total reflects a strategy of buying assets before competitive bidders can close them.

Why does the buyer side look so concentrated?

The buyer side in H1 narrowed to a small set of acquirers with the strongest cash flow and clearest strategic priorities. Mid-tier pharma and traditional biotech buyers largely stood aside, either digesting prior transactions or conserving balance sheet for upcoming clinical readouts.

The pecking order on the buy side ran:

1. Cash-rich category leaders. Lilly and a small group of peers with category-defining franchises.
2. Patent-cliff defenders. Major pharmas looking to backfill revenue before exclusivity expirations erode legacy franchises.
3. Selective strategic acquirers. Smaller transaction programs run by European and Japan-listed majors.

What does the H1 count tell CEOs?

For sitting biopharma CEOs, the H1 surge reframes three boardroom calculations:

• Pricing power. Sellers with de-risked Phase II data increasingly set the table in negotiations.
• Cost of capital. Acquirers that clear internal NPV thresholds in 60 months or less will outbid those that cannot.
• Integration capacity. Buyers with proven manufacturing and commercial scale can absorb assets faster than peers without that infrastructure.

What does H2 hold?

A first half that clears 50 deals sets a clear floor for the year. The H2 pace will depend on three forces:

• Clinical readouts. Phase II and Phase III data over the summer will reset valuations on assets that did not transact in H1.
• Financing markets. A more stable rate environment keeps strategic buyers in the market.
• Patent-cliff pressure. The largest pharmas face revenue erosion over the next five years and need backfill deals.

If H1 delivered 50 deals on Lilly-led volumes, the open question for H2 is whether the rest of the strategic buyer base can sustain the pace — and whether enough acquisition-ready biotechs remain to absorb the demand.